[{"address1": "2 Holzman Street", "address2": "Science Park PO Box 4081", "city": "Rehovot", "zip": "7670402", "country": "Israel", "phone": "972 8 940 6472", "fax": "972 8 940 6473", "website": "https://www.kamada.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.", "fullTimeEmployees": 378, "companyOfficers": [{"maxAge": 1, "name": "Mr. Amir  London", "age": 54, "title": "Chief Executive Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 611000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Chaime  Orlev", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 387000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eran  Nir", "age": 50, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 332000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jon R. Knight", "age": 57, "title": "Vice President of US Commercial Operations", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 307000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Boris  Gorelik", "age": 42, "title": "Vice President of Business Development & Strategic Programs", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 410000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Tsur", "age": 73, "title": "Co-Founder & Independent Deputy Chairman of the Board", "yearBorn": 1950, "fiscalYear": 2023, "totalPay": 252000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nir  Livneh B.A., L.L.B.", "age": 44, "title": "VP, General Counsel & Corporate Secretary", "yearBorn": 1979, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Hanni  Neheman", "age": 53, "title": "Vice President of Marketing & Sales", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Liron  Reshef", "age": 52, "title": "Vice President of Human Resources", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Shavit  Beladev", "title": "Vice President of Kamada Plasma", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.09, "open": 6.31, "dayLow": 6.3, "dayHigh": 6.39, "regularMarketPreviousClose": 6.09, "regularMarketOpen": 6.31, "regularMarketDayLow": 6.3, "regularMarketDayHigh": 6.39, "beta": 0.195, "trailingPE": 23.444443, "forwardPE": 17.583332, "volume": 38387, "regularMarketVolume": 38387, "averageVolume": 37096, "averageVolume10days": 32780, "averageDailyVolume10Day": 32780, "marketCap": 367267872, "fiftyTwoWeekLow": 4.74, "fiftyTwoWeekHigh": 6.53, "priceToSalesTrailing12Months": 2.3760004, "fiftyDayAverage": 5.8594, "twoHundredDayAverage": 5.52765, "currency": "USD", "enterpriseValue": 276216512, "profitMargins": 0.09751, "floatShares": 10223507, "sharesOutstanding": 57492300, "sharesShort": 26936, "sharesShortPriorMonth": 16064, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.0005, "heldPercentInsiders": 0.07312, "heldPercentInstitutions": 0.50099, "shortRatio": 0.94, "shortPercentOfFloat": 0.00090000004, "impliedSharesOutstanding": 58020200, "bookValue": 4.245, "priceToBook": 1.4911661, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": 1.443, "netIncomeToCommon": 15072000, "trailingEps": 0.27, "forwardEps": 0.31, "enterpriseToRevenue": 1.787, "enterpriseToEbitda": 9.715, "52WeekChange": -0.012965977, "SandP52WeekChange": 0.25443196, "lastDividendValue": 0.006, "lastDividendDate": 1371081600, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "KMDA", "underlyingSymbol": "KMDA", "shortName": "Kamada Ltd.", "longName": "Kamada Ltd.", "firstTradeDateEpochUtc": 1370007000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "a88fd904-380d-3754-b686-3fbaf4e080d7", "messageBoardId": "finmb_9002466", "gmtOffSetMilliseconds": -18000000, "currentPrice": 6.33, "targetHighPrice": 20.0, "targetLowPrice": 11.0, "targetMeanPrice": 14.66667, "targetMedianPrice": 13.0, "recommendationKey": "none", "numberOfAnalystOpinions": 3, "totalCash": 56547000, "totalCashPerShare": 1.022, "ebitda": 28432000, "totalDebt": 8559000, "quickRatio": 2.145, "currentRatio": 4.07, "totalRevenue": 154574000, "debtToEquity": 3.408, "revenuePerShare": 2.837, "returnOnAssets": 0.031600002, "returnOnEquity": 0.07045, "freeCashflow": -7769625, "operatingCashflow": 20314000, "earningsGrowth": 1.0, "revenueGrowth": 0.134, "grossMargins": 0.41997, "ebitdaMargins": 0.18394, "operatingMargins": 0.13279, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-02"}]